duros leuprolide

Alza Exercises Option For Cancer Treatment

Crescendo Pharmaceuticals Corporation has announced that ALZA Corporation has exercised its option to obtain a worldwide license to DUROS leuprolide (Viadur), a once-yearly implant for the palliative treatment of advanced prostate cancer. DUROS leuprolide is the first product to provide continuous, 12-month testosterone suppression with a single treatment. Under the terms of its license agreement Read more about Alza Exercises Option For Cancer Treatment[…]

Connetics And ALZA Announce Drug Delivery Collaboration

Connetics Corporation has entered into an agreement with ALZA Corporation to develop an advanced drug delivery system for Connetics’ proprietary recombinant human relaxin drug candidate. The development work will focus on applying ALZA’s implantable drug delivery technology, or DUROS system, to expand delivery options for relaxin. The current delivery system for Connetics’ relaxin formulation involves Read more about Connetics And ALZA Announce Drug Delivery Collaboration[…]